Clinical Trial Detail

NCT ID NCT03407976
Title Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Utah

gastric adenocarcinoma

Advanced Solid Tumor

colorectal cancer

transitional cell carcinoma

gastroesophageal junction adenocarcinoma


Pembrolizumab + Rivoceranib

Age Groups: adult senior

No variant requirements are available.